Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis: from pathophysiology to clinical practice

Background: SGLT-2 inhibitors are a novel class of antidiabetic drugs, recently - approved for the treatment of patients with T2DM. Their cardioprotective an...

Saved in:
Bibliographic Details
Main Authors: Patoulias, Dimitrios (Author) , Avranas, Konstantinos (Author)
Format: Article (Journal)
Language:English
Published: [2018]
In: Cardiovascular & hematological disorders, drug targets
Year: 2018, Volume: 18, Pages: 139-146
ISSN:2212-4063
DOI:10.2174/1871529X18666180206123149
Online Access:Resolving-System, Volltext: https://doi.org/10.2174/1871529X18666180206123149
Verlag, Volltext: http://www.eurekaselect.com/159592/article
Get full text
Author Notes:Dimitrios Patoulias, Alexandros Manafis, Christos Mitas, Konstantinos Avranas, Georgios Lales, Ioanna Zografou, Christos Sambanis and Asterios Karagiannis
Description
Summary:Background: SGLT-2 inhibitors are a novel class of antidiabetic drugs, recently - approved for the treatment of patients with T2DM. Their cardioprotective an...
Item Description:Gesehen am 18.02.2020
Physical Description:Online Resource
ISSN:2212-4063
DOI:10.2174/1871529X18666180206123149